Status(es): Active, not recruiting
Study Date(s): Friday, April 24, 2020 to Monday, March 1, 2021
Disease(s): acute myeloid leukemia (AML)
Age Group: 60 years and older
This phase II trial studies how well azacitidine and venetoclax chemotherapy with or without pembrolizumab works in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving...